The currency displayed has been switched according to the country of your account. The items in your cart will now appear in NZD.

You successfully switched to NZD currency. The items in your cart will now appear in NZD.

Our business will be closed from December 24 to January 2. Please check the last delivery dates for 2024 based on your location here. Wishing you happy holidays!

${loserAccounts} been merged into ${winnerAccount}.

A recent audit found these accounts to be duplicative. Addresses, order history and Q-global ordering for both accounts are now accessible via the ${winnerAccount} account. If something isn’t right, please contact us.

${loserAccounts} been merged into ${winnerAccount}.

A recent audit found these accounts to be duplicative. Addresses, qualified users, order history and Q-global ordering for both organisations are now accessible via the ${winnerAccount} account. If something isn’t right, contact us.

Positive and Negative Syndrome Scale

Positive and Negative Syndrome Scale

PANSS
  • Stanley R. Kay, PhD
  • Lewis A. Opler, MD
  • Abraham Fiszbein, MD
The Positive and Negative Syndrome Scale (PANSS™) helps measure the positive and negative syndromes of schizophrenia and other psychoses to develop treatment plans.  The PANSS is also helpful when studying the effects of medication (e.g., in clinical drug trials) because it allows you to determine which type of symptoms are being affected.

Choose from our formats

  • Test forms & reports

    Booklets, record forms, answer sheets, report usages & subscriptions

    3 options

    From AUD 156.86
    From AUD 156.86
  • Support materials

    Manuals, stimulus books, replacement items & other materials

    1 option

    From AUD 166.98
    From AUD 166.98
  • All products

    All tests and materials offered for PANSS

    4 options

    From AUD 156.86
    From AUD 156.86
    Filter by
    - of 4 results
    Prices include GST where applicable
    • PANSS Rating and Profile Forms Qty 25 (Print)
      A103000066630 Qualification Level B

      AUD 156.86

      text.product.itembackinstockonpurchaseinfo

      Estimated to ship:5 weeks
    • SCI-PANSS Record Forms Qty 25 (Print)
      A103000066631 Qualification Level B

      AUD 264.66

      text.product.itembackinstockonpurchaseinfo

      Estimated to ship:2 weeks
    • IQ-PANSS Record Forms Qty 25 (Print)
      A103000066632 Qualification Level B

      AUD 244.97

      text.product.itembackinstockonpurchaseinfo

    • PANSS Technical Manual (Print)
      A103000066634 Qualification Level B

      AUD 166.98

      text.product.itembackinstockonpurchaseinfo

    - of 4 results

    Overview

    Publication date:
    2006

    Completion time:
    30-40 minutes per form

    Age range:
    18+

    Qualification level:
    B

    Qualification Level

    Level A

    This approval level enables you to buy our assessments that require no professional degree, accreditation, organization membership, or license/certificate.

    Level B

    This approval level enables you to buy our assessments requiring A or B qualification levels.

    Level C

    This approval level enables you to buy all our assessments.

    Norms:
    Normative data was gathered from a sample of 240 medicated schizophrenics. The major scales were all found to exhibit the characteristic Gaussian (bell-shaped) distribution curves, without significant skewness or kurtosis, which was taken to indicate that the scores are normally distributed in the comparison sample. Complete normative data are provided in the PANSS Manual.

    Scoring options:
    Hand scored

    Forms:
    Professional – Number of items: 33, Observer (IQ-PANSS) – Number of items: 98, Interview (SCI-PANSS) – Number of items: 179

    Product Details

    The Positive and Negative Syndrome Scale (PANSS™) is based on findings that schizophrenia comprises at least two distinct syndromes: the positive syndrome, consisting of productive symptoms; and the negative syndrome, consisting of deficit features. It is useful when developing treatment plans because you can focus on the type of symptoms the patient is experiencing. The PANSS is also helpful when studying the effects of medication (e.g., in clinical drug trials) because it allows you to determine which type of symptoms are being affected. 

    Key Areas Measured

    • Positive Scale 
    • Negative Scale 
    • General Psychopathology Scale 
    • Supplemental Aggression Risk Profile 

    Components

    Structured Clinical Interview for PANSS (SCI-PANSS)
    To optimise the instrument’s objectivity, the SCI-PANSS was developed to secure reliable information. The SCI-PANSS can be used to gather information objectively prior to completing the PANSS Rating and Profile Form.

    Informant Questionnaire (IQ-PANSS)
    The IQ-PANSS evaluates phenomenological presentation. Through item definitions, statements, and questions, the questionnaire ensures that all information related to behavioral presence, frequency, and responsiveness is obtained during interviews with family members, healthcare providers, or other informants. The IQ-PANSS information is then used to assist in completing the PANSS Rating and Profile Form.

    How to Use

    The PANSS is a hand scored instrument. It can be scored using the standard Dimensional scoring or the Pentagonal scoring method. The Pentagonal method uses 25 PANSS items organised into five scales: Negative, Positive, Dysphoric Mood, Activation, and Autistic Preoccupation.

    Reliability and Validity

    Thirty years of research support the use of the PANSS as a psychometrically sound measure of the presence and severity of symptoms of schizophrenia. The scales have demonstrated excellent internal consistency (coefficient alpha and split-half reliability) and consistency over time (test-retest reliability) while still being sensitive to change. The PANSS Positive and Negative symptom ratings are highly correlated with the Anderson method for evaluation, and the General Psychopathology scale has demonstrated significant associations with the NIMH Clinical Global Impression Scale.
    Psychopharmacological research supports the PANSS’ construct, discriminative, convergent, and predictive validity. In addition, the American Food and Drug Administration (FDA) is supportive of the use of the PANSS as an outcome measure in clinical trials assessing drug efficacy, given the volume of studies that support its sensitivity to medication and other treatment effects when used longitudinally.